Gastrointestinal Stromal Tumor Market is expected to grow during the Forecast Period (2019-2032), DelveInsight | Major Companies- Advenchen Laboratories, Deciphera Pharmaceuticals, Pfizer, and Several Others.

DelveInsight's Gastrointestinal Stromal Tumor Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Gastrointestinal Stromal Tumor Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Gastrointestinal Stromal Tumor market report cover emerging drugs, current treatment practices, market share of the individual therapies, and the current forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best opportunities and assess the underlying potential of the market.

Get access to a free copy of our latest sample report @ https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastrointestinal Stromal Tumor: Overview

A gastrointestinal stromal tumor (GIST) is rare cancer affecting the digestive tract or nearby structures within the abdomen. It is a sarcoma that arises either from cells called interstitial cells of cajal (ICCs) or from less differentiated stem cells or precursor cells that can develop into ICCs. Because GIST cancers arise from the GI tract wall, they are usually attached to the outside of the involved organ, growing outward; this is sometimes referred to as exophytic. Occasionally a GIST may grow inward through the muscle layer of the GI tract wall and then develop partly inside the digestive tract lumen; this is sometimes called endophytic.

Some of the key facts of the Gastrointestinal Stromal Tumor Market Report

• As per DelveInsight, the total incident cases of Gastrointestinal Stromal Tumors (GIST) in the US were observed to be 5,090 in 2017.
• The stages of Gastrointestinal Stromal Tumor (GIST) are classified into three categories, i.e., localized, regional, distant, and unknown. As per DelveInsight's estimates, localized cases account for approximately 60% of the total cases.
• According to Ma et al. (2015), Gastrointestinal Stromal Tumor (GIST) is more common in males than females with a rate ratio of 1.35.

Download Free Sample Report Now @ https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastrointestinal Stromal Tumor Market

Gastrointestinal Stromal Tumor market size is anticipated to increase during the study period owing to the increasing incident population and rising awareness of Gastrointestinal Stromal tumors in the 7MM. The expected launch of emerging therapies and the research and development activities of pharmaceutical companies will also fuel the market growth during the forecast period.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Gastrointestinal Stromal Tumor market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Gastrointestinal Stromal Tumor market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Gastrointestinal Stromal Tumor Treatment Market

The current treatment options for the GIST include surgery, ablation and embolization, targeted therapy, chemotherapy, radiation therapy, and supportive care. Surgery is usually the main treatment for GISTs that haven't spread. The goal of the surgery is to remove all of cancer. The type of surgery needed depends on the location and size of the tumor. If the tumor is small, it often can be removed along with a small area of normal tissue around it. This is done through a cut (incision) in the skin. Unlike many other cancers, GISTs almost never spread to the lymph nodes, so removing nearby lymph nodes is usually not needed. If the tumor is large or growing into other organs, the surgeon might still be able to remove it entirely. To do this, parts of organs (such as a section of the intestines) might need to be removed. The surgeon might also remove tumors that have spread elsewhere in the abdomen, such as the liver.

Gastrointestinal Stromal Tumor Market Insights

A large number of GIST subtypes based on the gene mutation involve offers an opportunity for the development of novel therapies, as the current therapies are specific to only a few subtypes. The current therapies are associated with some serious side effects. The recurrence of the GIST is also a very big concern. Hence, there is an unmet need for therapies with fewer side effects and effective against the recurrence of GIST.

Download Free Sample Report Now @ https://www.delveinsight.com/sample-request/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastrointestinal Stromal Tumor Epidemiology

The epidemiology section covers insights into the historical and current Gastrointestinal Stromal Tumor patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Gastrointestinal Stromal Tumor Drugs & Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Gastrointestinal Stromal Tumor market or expected to get launched in the market during the study period. The analysis covers Gastrointestinal Stromal Tumor market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report's Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Gastrointestinal Stromal Tumor Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Browse More Related Reports @ https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Gastrointestinal Stromal Tumor Emerging Therapies
The available therapeutic treatment options in GIST Landscape mainly includes surgery and targeted drug therapy. The market size shall grow during the forecast period owing to the launch of upcoming therapies. The market size is expected to increase at a significant rate during the study period.

Gastrointestinal Stromal Tumor Companies
• Advenchen Laboratories
• Deciphera Pharmaceuticals
• Pfizer
• Bayer
• Blueprint Medicines Corporation
• Novartis
• Arog Pharmaceuticals
• Taiho Oncology, and Several Others

Gastrointestinal Stromal Tumor Drugs
• AL3818
• Ripretinib
• TAS-116
• Crenolanib
• Avapritinib
• Gleevec
• Vitrakvi
• Stivarga, and Several Others

Request for more information @ https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of content
1. Key Insights
2. Executive Summary
3. Competitive Intelligence Analysis
4. Market Overview at a Glance
5. Disease Background and Overview
6. Patient Journey
7. Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Gastrointestinal Stromal Tumor Treatment
11. Marketed Products
12. Emerging Therapies
13. Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Consult with our Business Expert @ https://www.delveinsight.com/report-store/gastrointestinal-stromal-tumor-gist-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.

This release was published on openPR.